Komori
Astellas Pharma (4503) · InitiativeAchieved

Voluntary discontinuation of the Phase 3 trial of nacotinib

First written in FY2017. 1 of 1 entries say "Achieved", first in FY2017. Latest entry: FY2017.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Voluntary Discontinuation of the Phase III Trial of ナコチニブA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2017AchievedAnnual report

    「試験への患者組み入れを自主的に中止するとともに、ナコチニブの投与を中止することを決定しました。」

    独立データモニタリング委員会の勧告を受け、2017年5月にナコチニブの第3相試験への患者組み入れと投与の中止を決定した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Voluntary discontinuation of the Phase 3 trial of nacotinib | Astellas Pharma Inc. (4503) | Komori